magl

MAGL-IN-5 is a non-selective lipase inhibitor.

MAGL-IN-21 (Compound (S)-6) is a selective inhibitor of monoacylglycerol lipase (MAGL) with an IC50 of 1.59 nM.

MAGL-IN-9, also referred to as compound 16, is a reversible inhibitor of monoacylglycerol lipase (MAGL) with a potent IC50 value of 2.7 nM [1].

MAGL-IN-8 (compound 13) is a reversible inhibitor of monoacylglycerol lipase (MAGL) with an IC50 value of 2.5 ± 0.4 nM for human MAGL (hMAGL) [1].

MAGL-IN-11 (compound 29) is a selective, reversible inhibitor of monoacylglycerol lipase (MAGL) with potential applications in inflammation, cancer, and antioxidant research [1].

MAGL-IN-10, a reversible monoacylglycerol lipase (MAGL) inhibitor, exhibits favorable ADME properties and low in vivo toxicity. It is applicable in the study of cancer, neurological disorders, and inflammatory pathologies [1].

MAGL-IN-18 (compound 118) serves as a highly potent inhibitor of Monoacylglycerol lipase (MAGL), demonstrating an IC 50 value of 0.03nM.

MAGL-IN-20 (compound ±34) is a reversible inhibitor of monoacylglycerol lipase (MAGL). It exhibits significant antiproliferative activity against a range of cancer cell lines, including H460, HT29, CT-26, Huh7, and HCCLM-3.

PROTACMAGLdegrader-1 is an orally active PROTAC agent that simultaneously targets both monoacylglycerol lipase (MAGL) and the E3 ubiquitin ligase MDM2. It functions by degrading MAGL and inhibiting the interaction between MDM2 and p53. Additionally, PROTACMAGLdegrader-1 has partial blood-brain barrier (BBB) penetration and can induce apoptosis in glioblastoma stem cells (GSC).

JNJ-42226314 is a highly selective non-covalent monoacylglycerol lipase (MAGL) inhibitor with anti-injury effects.JNJ-42226314 shows efficacy via endogenous cannabinoid-2-acryloylglycerol (2-AG) in models of neuropathic pain and inflammatory pain.

JZL195 is a selective and efficacious dual FAAH/MAGL inhibitor.

KML29 is highly selective and effective monoacylglycerol lipase (MAGL) inhibitor. It has effective inhibition of human/mouse/rat MAGL (IC50: 5.9/15/43 nM). It has not inhibitory for FAAH (IC50 > 50 μM). It also effectively and selectively blocks hydrolysis of 2-arachidonoylglycerol (2-AG) in mice (IC50: 2.5 nM, 2-AG; >50 μM, AEA).

Euphol, an alcohol tetracyclic triterpene, has a wide range of pharmacological properties and is considered to have anti-inflammatory action.

MJN110 (Cravatt Reagent) is a potent and selective MAGL inhibitor. Cravatt Reagent inhibits MAGL (IC50 = 9.1 nM). MJN110(Cravatt Reagent) Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.

MAGL-IN-1 is a selective and potent monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 80 nM.

MAGL-IN-19 (compound 7o) is a highly effective and selective inhibitor of MAGL.

MAGL-IN-222 (Compound ZQ-7) is a covalent inhibitor that targets monoacylglycerol lipase (MAGL), with an IC50 of 42.31 μM. It reduces the breakdown of 2-arachidonoylglycerol (2-AG), enhancing intracellular 2-AG levels, thereby inhibiting the proliferation and migration of MDA-MB-231 breast cancer cells. MAGL-IN-222 is applicable in breast cancer research and related diseases.

MAGLLigand-Linker Conjugate 1 is a compound that combines a MAGL ligand with a linker. This conjugate serves as an essential component for synthesizing the PROTAC degrader, known as PROTACMAGLdegrader-1.

FAAH MAGL-IN-1, also known as compound SIH 3, is a highly effective inhibitor of FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase). It exhibits IC50 values of 31 nM and 29 nM against FAAH and MAGL, respectively. This compound shows promising potential for advancing research in the field of neuropathic pain [1].

FAAH MAGL-IN-2, a potent and reversible inhibitor of FAAH and MAGL, demonstrates oral activity and the ability to cross the blood-brain barrier. It exhibits IC50 values of 11 nM for FAAH and 36 nM for MAGL (Ki values of 28 nM and 60 nM, respectively). This compound shows promise for neuropathic pain research, without impairing locomotion [1].

MAGL-IN-6, a potent inhibitor of MAGL (IC50: 4.71 nM), can be utilized for studying neurological diseases.

FAAH MAGL-IN-3 (Compound 10) is an irreversible dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) with an IC50 of 179 nM for FAAH and 759 nM for MAGL. FAAH MAGL-IN-3 exhibited minimal permeability in the PAMPA (parallel artificial membrane permeability assay).

MAGL-IN-14 (compound 2) serves as a potent MAGL inhibitor, exhibiting IC50 values of 0.00289 μM in HEK293 cells and 0.002 μM in PC3 cells [1].

MAGL-IN-15 (Compound 6), a MAGL inhibitor, holds potential for research into diseases and disorders associated with the regulation of endocannabinoid system signaling activities [1].